Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: February 2014 (Specific date: February 4, 2014)
Context: This filing serves as a Director Declaration in conformity with Listing Rule 9.6.14, notifying the market of a new external appointment by a Non-Executive Director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding director appointments and does not contain financial statements or performance data.
Material Changes
No material financial changes are reported. The filing discloses a corporate governance update: Sir Robert Wilson, a Non-Executive Director of GSK, was appointed Chairman of Riverstone Energy Limited on May 23, 2013, prior to Riverstone's listing on the London Stock Exchange on October 29, 2013.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on financial performance, or specific risk factors. The only disclosed contingency relates to the external directorship of Sir Robert Wilson at Riverstone Energy Limited.
Investor Verification Checklist
- Verify the independence and potential conflicts of interest regarding Sir Robert Wilson's role as Chairman of Riverstone Energy Limited.
- Confirm the listing status and performance of Riverstone Energy Limited on the London Stock Exchange.
- Review GSK's annual Form 20-F for comprehensive financial data, as this Form 6-K contains no financial metrics.